US Food and Drug Administration (USFDA) has completed inspection at Granules India’s Gagillapur facility in Hyderabad, Telangana. The inspection, conducted from August 26, 2024 to September 06, 2024, concluded with six observations.
The recent inspection covered both Current Good Manufacturing Practice (cGMP) and Pre-Approval Inspection (PAI) processes. Granules India is committed to addressing the observations promptly and will submit its response to the USFDA within the stipulated timeframe. The Gagillapur facility continues to play a vital role in the company’s global operations, ensuring the supply of high-quality pharmaceutical products to markets worldwide.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
